FDA Orange Book
Generic for Dynacirc
Dynacirc contains isradipine. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Dynacirc is isradipine. 2 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
Run it in Rivvi
Map Dynacirc and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Dynacirc products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| capsule, oral | 2.5MG | Discontinued | None | 2 | AB |
| capsule, oral | 5MG | Discontinued | None | 2 | AB |
NDA 019546, held by SMITHKLINE BEECHAM CORP DBA GLAXOSMITHKLINE. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic isradipine
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC | 077317 | AB (A-rated, therapeutically equivalent) | January 5, 2006 | 2.5MG, 5MG |
| ELITE LABORATORIES INC | 077169 | AB (A-rated, therapeutically equivalent) | April 24, 2006 | 2.5MG, 5MG |
Questions
Is there a generic for Dynacirc?
Yes. The generic name for Dynacirc is isradipine. 2 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
What is the generic name for Dynacirc?
The active ingredient in Dynacirc is isradipine, per the FDA Orange Book.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.